UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | December 14, 2005 |
Anadys Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 000-50632 | 22-3193172 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 3115 Merryfield Row, San Diego, California | | 92121 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | (858) 530-3600 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On December 14, 2005, the Company was informed that Jason S. Fisherman, M.D., has decided to resign from the Board of Directors effective December 31, 2005 to allow himself to devote more time to other business matters. Dr. Fisherman will continue to assist the Company with strategic direction as a member of the Company's Clinical and Scientific Advisor Board. Dr. Fisherman is currently a member of the Compensation Committee of the Board of Directors.
George A. Scangos, Ph.D., a member of the Company's Board of Directors, will assume the position of Chairman of the Board effective December 31, 2005. Steven H. Holtzman, also a member of the Company’s Board of Directors, has been appointed to the Compensation Committee of the Board of Directors effective December 31, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Anadys Pharmaceuticals, Inc. |
| | | | | |
| December 16, 2005 | | By: | | /s/ Jennifer K. Crittenden
|
| | | | |
|
| | | | | Name: Jennifer K. Crittenden |
| | | | | Title: Vice President, Finance |
